Consensus Statement on Proton Therapy in Mesothelioma.
Journal
Practical radiation oncology
ISSN: 1879-8519
Titre abrégé: Pract Radiat Oncol
Pays: United States
ID NLM: 101558279
Informations de publication
Date de publication:
Historique:
received:
15
03
2020
revised:
26
04
2020
accepted:
13
05
2020
pubmed:
29
5
2020
medline:
19
8
2021
entrez:
29
5
2020
Statut:
ppublish
Résumé
Radiation therapy for mesothelioma remains challenging, as normal tissue toxicity limits the amount of radiation that can be safely delivered to the pleural surfaces, especially radiation dose to the contralateral lung. The physical properties of proton therapy result in better sparing of normal tissues when treating the pleura, both in the postpneumonectomy setting and the lung-intact setting. Compared with photon radiation, there are dramatic reductions in dose to the contralateral lung, heart, liver, kidneys, and stomach. However, the tissue heterogeneity in the thorax, organ motion, and potential for changing anatomy during the treatment course all present challenges to optimal irradiation with protons. The clinical data underlying proton therapy in mesothelioma are reviewed here, including indications, advantages, and limitations. The Particle Therapy Cooperative Group Thoracic Subcommittee task group provides specific guidelines for the use of proton therapy for mesothelioma. This consensus report can be used to guide clinical practice, insurance approval, and future research.
Identifiants
pubmed: 32461036
pii: S1879-8500(20)30117-X
doi: 10.1016/j.prro.2020.05.004
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
119-133Informations de copyright
Copyright © 2020 American Society for Radiation Oncology. Published by Elsevier Inc. All rights reserved.